NorthStar Medical Radioisotopes, LLC is an early stage company destined to take advantage of the challenging, ever changing and dynamic nuclear medicine market. NorthStar Medical Radioisotopes is strategically equipped to become a key player in this market with products and services for diagnostic and therapeutic radioisotopes.

Rapid market expansion is occurring in diagnostic radioisotope enhanced imaging procedures (CatScan, MRI, X-Ray and ultrasound) and more importantly radioisotopes are being employed as a therapy for cancer, leukemia, heart disease, Parkinson’s Disease and other diseases. There is a fundamental belief that herein lies the cure for deadly and debilitating diseases being treated with molecules which can seek and attach radioisotopes to tumors and cancerous growths. This overall market is estimated to be a $10 billion market that is expected to realize an annual growth rate in excess of 10% per year for the next five (5) years.

Our Mission

NorthStar's ability to provide solutions in the areas where no solution exists, establishing sourcing of hard to get radioisotopes and a comprehensive distribution channel will brand NorthStar as:

"Enabling the future of nuclear medicine"

Company Profile

NorthStar Medical Radioisotopes, LLC, ("NorthStar" or the "Company") was founded in 2006 by the principals of NorthStar Growth Partners, LLC ("NGP") located in Madison, WI. NGP has obtained exclusive access to worldwide patents through a License Agreement obtained from PG Research Foundation¹. The patented technologies (equipment, methods and procedures – collectively the "Technology") have many separable market applications and broadly contain methods and instrumentation which solve a myriad of problems in producing ultrapure radioisotopes. One such market is for nuclear medicine and NGP has given the Company an exclusive worldwide right to exploit the technology in this marketplace. The Company's management has recognized that these technologies can be successfully deployed into the explosive, emerging, and ever-changing nuclear medicine market and will have the ability to revolutionize the methods and processes used in the production and distribution of radioisotopes, particularly short-lived ones. The Company will create instrumentation and associated disposables for radionuclide separation, dosing, and dispensing for sale to research laboratories and commercial suppliers of these radiopharmaceuticals throughout United States.

This Company will enable researchers to expand diagnostic and therapy choices of desired isotopes to conduct research upon, and mitigate a significant portion of the risk associated with the production and conjugation (linking together), and administration of the radiopharmaceutical. NorthStar's technology will be incorporated and utilized by these research laboratories and commercial nuclear pharmacies engaged in providing dose preparation for support of groundbreaking clinical studies for new therapies and diagnostics in Nuclear Medicine. Utilizing NorthStar's extensive network of contacts throughout the world, NorthStar will be engaged in providing the newest isotopes in sufficient quantity to meet the needs of today's researchers and tomorrow's pharmaceutical developers. NorthStar intends to set new standards for safety, purity and dose consistency.

¹ PGRF is the PG Research Foundation Inc., a GCI Company, located at 8205 South Cass Avenue, Suite 106 • Darien Illinois. It is a technology development company with a high level of expertise in chemical separation knowledge and significant experience in separating nuclear Isotopes. Its founder, E. Phil Horwitz is a retired Senior Scientist of Argonne National Laboratory in Argonne, IL and has a distinguished career in this area of science.